Microbiome Therapeutics Market Size and Forecasts (2020-2030)

Microbiome Therapeutics Market Size and Forecasts (2020-2030)

Microbiome Therapeutics Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Send Enquiry
Item ID: TIPRE00027698 Category: Tag:

$3,185 – $5,985

Description

The microbiome therapeutics market is expected to grow from US$ 375.92 million in 2022 to US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030.

The human microbiome includes all the microorganisms and their related metabolites/products identified in and around the human body. Technological advancement has enabled the examination of the pleiotropic effects of the human gut microbiome in maintaining health and diseases. With the extensive potential of microbes in human health, they hold enormous potential to be used as therapeutics for disease management. Microbiome therapy holds great promise to treat any severe type of disease condition and acts as the potential source to achieve the objective of personalized therapy by overcoming key issues like interpersonal variability and stability in every type of environment. Strategies such as fecal microbiota transplantation (FMT) or probiotics that rely on the administration of exogenous microbes could be used to manage dysbiosis-related disorders.

Potential of Gut Microbiota in Maintaining Human Health drives the growth the Microbiome Therapeutics Market

Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) released statistics showing that GERD prevalence ranges from 18% to 28% in North America, 23% in South America, and 9–26% in Europe. Therefore, in the upcoming years, the increasing frequency of gastrointestinal disorders will fuel the market expansion.

By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.

The growing recognition of the microbiome’s importance in human health and disease has encouraged rigorous research and development efforts to further understand the human microbiome and develop microbiome therapeutics. It has helped develop potential therapeutics and identify hindrances. Advancements in technology and research tools have also contributed to growing R&D. Next-generation sequencing and metagenomic analysis have allowed for a more comprehensive and detailed study of the microbiome. These tools enable researchers to identify specific microbial species and their functions, as well as track changes in the microbiome over time. Regulatory agencies, such as the FDA, are also supporting R&D efforts in the field of microbiome therapeutics. The FDA has established guidelines for FMT and has developed interest in advancing the field through regulatory pathways to ensure safety and efficacy. This support from regulatory agencies provides a framework for companies to develop and test microbiome-based therapies, giving investors confidence in the potential success of these treatments. Overall, the increased interest and funding in microbiome therapeutics are driving more research and development efforts. This will lead to a better understanding of the human microbiome and the development of targeted therapies that can modulate the microbiome to improve human health.

The microbiome therapeutics market is divided on the basis of type, application, end user, and geography. The microbiome therapeutics market is divided on the basis of type, application, and end user. Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. By application, the microbiome therapeutics market is segmented into metabolic disorders and obesity, C. difficile infection, and inflammatory bowel diseases. In terms of end users, the microbiome therapeutics market is classified as hospitals and clinics, ambulatory surgery centers, and home care.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the microbiome therapeutics market. North America accounts for a significant market share owing to the growing incidences of C. difficile cases, technological advances, and growing awareness about the importance of gut microbiota. The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treat various conditions. Additionally, the dominance of this country in the microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

An emphasis on research and innovation has yielded a significant understanding of the impact of gut microbiota on health, providing a solid foundation for microbiome-based therapeutics. A supportive regulatory environment for biotechnology and pharmaceuticals in Canada has encouraged companies to invest in microbiome-focused research and development. Additionally, increased venture capital investments and government funding have infused capital into this research. In January 2020, the Government of Canada, along with its partners, invested US$ 18 million in crucial microbiome research.

The rising awareness among Canadians about the importance of gut health and microbiome in overall well-being has spurred consumer demand for microbiome-based products. Moreover, the widespread implementation of initiatives such as the Canadian Microbiome Initiative (CMI) makes working with partners and stakeholders easier in Canada. This makes it possible to concentrate research efforts on the development of microbiome therapies. Collaborations and partnerships between academic institutions, biotechnology firms, and healthcare organizations have accelerated research and development efforts. Moreover, Canadian companies are exploring international markets, expanding the reach of microbiome therapeutics. All these factors combined indicate a promising trajectory for microbiome therapeutics in Canada.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the microbiome therapeutics market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

Procedures Segment, by Type, to Account Larger Share Microbiome Therapeutics Market During 2022–2030

According to our new research study on “Microbiome Therapeutics Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis,” the microbiome therapeutics market size is expected to grow from US$ 375.92 million in 2022 and to reach a value of US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030. Key factors driving the market growth are potential of gut microbiota in maintaining human health and inflow of funds to ameliorate microbiome discovery pipeline. However, high cost of development and production hinders the microbiome therapeutics market growth.

Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome’s potential to treat and promote a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements in microbiome research, which are raising awareness of the gut-brain connection and offering the possibility of developing cutting-edge treatments for a range of medical conditions. The pipeline of microbiome therapeutics is dynamic and diverse, aimed at tackling an extensive array of medical conditions and offering novel treatments that harness the human microbiome. More microbiome-based treatments may become available as this field of study develops, opening up new avenues for market expansion. There is a growing need for novel and more efficient treatments due to the rising prevalence of illnesses like metabolic disorders, obesity, irritable bowel syndrome, and inflammatory bowel disease. Microbiome-based treatments present a cutting-edge method of treating these ailments. This consequently generates a large window of opportunity for market expansion in the near future.

Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. The therapeutics segment is further bifurcated into faecal microbiota transplantation (FMT), prebiotics & probiotics, and others. Fecal microbiome therapeutic technique is an emerging technique that has proven to be highly effective in patients with recurring Clostridioides difficile infection (CDI). Growing FMT product approvals by the Food and Drug Administration (FDA) for preventing the recurrence of CDI is fueling the growth of the segment. For instance, in November 2022, the US FDA approved Rebyota, the first fecal microbiota product used for the prevention of CDI recurrence in individuals aged above 18 years.

Based on the application, the microbiome therapeutics market is classified into metabolic disorders and obesity, C. difficile infection, inflammatory bowel diseases, and others. In 2022, the C. difficile infection segment held the largest share of the market and is expected to register the highest CAGR during 2022–2030. When someone takes antibiotics, good bacteria in the gut are destroyed for a few months. During this time, patients can get sick from Clostridioides difficile, a bacteria that often causes severe or even deadly diarrhea. According to CDC, in 2021, ~118,000 hospitalized patients suffered from C. difficile infection in the US. To prevent and treat C. difficile infection, the gut microbiome of the patient needs to be increased by giving microbiome therapeutics. Due to the increase in the number of C. difficile infections, companies are focusing on developing microbiome therapeutics for the treatment. For instance, in April 2023, the US FDA approved Vowst, the first fecal microbiota used to prevent the recurrence of C. difficile infection.

Based on the end user, the microbiome therapeutics market is classified into hospitals and clinics, ambulatory surgery centers, home care, and others. In 2022, the hospitals and clinics segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2030. Hospitals are the fastest-growing end users of the microbiome therapeutics market. Hospitals are the primary healthcare centers patients seek for their first aid and treatment. The number of patients visiting hospitals is comparatively higher than other healthcare centers. These centers offer various services and provide good-quality treatment to patients. In many hospitals, the treatment fee is reimbursed; also, medicines are readily available in these healthcare centers. The implementation of advanced treatment technologies in hospitals has paved the way for improved and early detection of disease, as well as supported research related to disease treatment. Medical services are increasingly offered due to their rising affordability of treatment and awareness among people. It is a part of the ecosystem of many countries, as it contributes significantly toward the country’s GDP growth.

Enterome, Finch Therapeutics Group Inc, Caelus Health, Ferring Pharmaceuticals, Pendulum Therapeutics Inc., AOBiome, Seres Therapeutics, Vedanta Biosciences, COST-BRY Pty Ltd (BiomeBank) and YSOPIA Bioscienceare. are among the leading companies operating in the global microbiome therapeutics market.

Companies operating in the microbiome therapeutics adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies in the microbiome therapeutics. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall microbiome therapeutics growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In November 2023, the company obtained its first worldwide regulatory approval for a donor-derived microbiome medicinal product in November 2022 from the Therapeutic Goods Administration (TGA).

• In February 2023, Ferring Pharmaceuticals has announced that RBX2660, also known as Rebyota, is a fecal microbiota product that can be used for treatment in the United States. Ferring has provided adults with a much-needed new therapeutic option for recurrent C diff infection with the introduction of Rebyota. The introduction of this revolutionary live biotherapeutic based on microbiota offers an innovative approach to treating people with recurrent C diff (CDI) infection.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the microbiome therapeutics market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Microbiome Therapeutics Market, by Geography
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Microbiome Therapeutics Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Microbiome Therapeutics Market – Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Potential of Gut Microbiota in Maintaining Human Health
5.1.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
5.2 Market Restraints
5.2.1 High Cost of Development and Production
5.3 Market Opportunities
5.3.1 Increasing R&D to Gain Better Understanding of Human Microbiome
5.4 Future Trends
5.4.1 Technological Advancement in Human Microbiome Therapeutics
5.5 Impact Analysis:
6. Microbiome Therapeutics Market – Global Market Analysis
6.1 Microbiome Therapeutics Market Revenue (US$ Mn), 2020 – 2030
7. Global Microbiome Therapeutics Market – Revenue and Forecast to 2030 – by Type
7.1 Overview
7.2 Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 Procedure
7.3.1 Overview
7.3.2 Procedure: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Therapeutics
7.4.1 Overview
7.4.2 Therapeutics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
8. Global Microbiome Therapeutics Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Metabolic Disorder and Obesity
8.3.1 Overview
8.3.2 Metabolic Disorder and Obesity: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 C. Difficile Infection (CDI)
8.4.1 Overview
8.4.2 C. Difficile Infection (CDI): Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Inflammatory Bowel Disease
8.5.1 Overview
8.5.2 Inflammatory Bowel Disease: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Microbiome Therapeutics Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Microbiome Therapeutics Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
9.4.1 Overview
9.4.2 Ambulatory Surgical Centers: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Homecare
9.5.1 Overview
9.5.2 Homecare: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10. Microbiome Therapeutics Market – Geographical Analysis
10.1 North America Microbiome Therapeutics Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.4 North America: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.5 North America: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Microbiome Therapeutics Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.6.1.4 US: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.6.1.5 US: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.4 Europe: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.5 Europe: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Microbiome Therapeutics Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.3.4 France: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.3.5 France: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Microbiome Therapeutics Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.1.4 China: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.1.5 China: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.3.4 India: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.3.5 India: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Microbiome Therapeutics Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.4 South & Central America: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.5 South & Central America: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Microbiome Therapeutics Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
11. Microbiome Therapeutics Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Microbiome Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Enterome
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Finch Therapeutics Group Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Caelus Health
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Ferring Pharmaceuticals
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Pendulum Therapeutics INC
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AOBiome
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Seres Therapeutics
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Vedanta Biosciences
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 COST-BRY Pty Ltd (BiomeBank)
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 YSOPIA Bioscience
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. Microbiome Therapeutics Market Segmentation
Table 2. Global Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Microbiome Therapeutics Market, by Type– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. US Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 9. US Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 10. US Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 25. UK Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 26. UK Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 31. France Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. France Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 33. France Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 34. France Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 43. Rest of Europe Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 49. Rest of Europe Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 50. Rest of Europe Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 52. Asia Pacific Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 53. Asia Pacific Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 54. Asia Pacific Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 55. China Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. China Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 57. China Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 58. China Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 60. Japan Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 61. Japan Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 62. Japan Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 63. India Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 64. India Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 65. India Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 66. India Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 67. Australia Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 68. Australia Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 69. Australia Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 70. Australia Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 71. South Korea Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 72. South Korea Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 73. South Korea Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 74. South Korea Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 75. Rest of Asia Pacific Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 108. Rest of Asia Pacific Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 109. Rest of Asia Pacific Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 110. Rest of Asia Pacific Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 111. Middle East & Africa Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 112. Middle East & Africa Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 113. Middle East & Africa Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 114. Middle East & Africa Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 115. Saudi Arabia Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 116. Saudi Arabia Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 117. Saudi Arabia Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 118. Saudi Arabia Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 119. South Africa Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 120. South Africa Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 121. South Africa Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 122. South Africa Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 123. UAE Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 124. UAE Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 125. UAE Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 126. UAE Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 127. Rest of Middle East Africa Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 128. Rest of Middle East Africa Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 129. Rest of Middle East Africa Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 130. Rest of Middle East Africa Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 131. South & Central America Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 132. South & Central America Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 133. South & Central America Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 134. South & Central America Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 135. Brazil Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 136. Brazil Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 137. Brazil Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 138. Brazil Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 139. Argentina Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 140. Argentina Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 141. Argentina Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 142. Argentina Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 143. Rest of South & Central America Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 144. Rest of South & Central America Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 145. Rest of South & Central America Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 146. Rest of South & Central America Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 147. Recent Inorganic Growth Strategies in the Microbiome Therapeutics Market
Table 148. Recent Organic Growth Strategies in Microbiome Therapeutics Market
Table 149. Glossary of Terms, Microbiome Therapeutics Market

LIST OF FIGURES

Figure 1. Microbiome Therapeutics Market Segmentation, By Geography
Figure 2. Global – PEST Analysis
Figure 3. Microbiome Therapeutics Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Microbiome Therapeutics Market Revenue (US$ Mn), 2020 – 2030
Figure 6. Microbiome Therapeutics Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 7. Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 8. Procedure: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Therapeutics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
Figure 11. Metabolic Disorder and Obesity: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. C. Difficile Infection (CDI): Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Inflammatory Bowel Disease: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Otehrs: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Microbiome Therapeutics Market Revenue Share, End User, 2022 & 2030 (%)
Figure 16. Hospitals and Clinics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Ambulatory Surgical Centers: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Homecare: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. North America: Microbiome Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 21. North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. North America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 23. US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Europe Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 27. Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Europe Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 29. UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Asia Pacific Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 37. Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Asia Pacific Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 39. China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. Middle East & Africa Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 54. Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. Middle East & Africa Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 56. Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 57. South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 58. UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 59. Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 60. South & Central America Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 61. South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 62. South & Central America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 63. Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 64. Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 65. Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 66. Growth Strategies in Microbiome Therapeutics Market

The List of Companies – Microbiome Therapeutics Market 
o Enterome
o Finch Therapeutics Group Inc
o Caelus Health
o Ferring Pharmaceuticals
o Pendulum Therapeutics Inc.
o AOBiome
o Seres Therapeutics
o Vedanta Biosciences
o COST-BRY Pty Ltd (BiomeBank)
o YSOPIA Bioscienceare

Reviews

There are no reviews yet.

Be the first to review “Microbiome Therapeutics Market Size and Forecasts (2020-2030)”